Amanta Healthcare Q1FY27: Steady growth, near-peak utilisation, and a capex-led setup for FY27

Amanta Healthcare entered Q1FY27 with a familiar operating pattern: steady revenue growth, disciplined production, and a clear push to unlock the next leg of scale through capacity additions and structural cost actions. For the quarter ended June 30, 2026, revenue rose to INR 69 crore from INR 65 crore in Q1FY26, a 5 percent year-on-year increase on broadly the same installed capacity. Profitability was stable at the operating line, with EBITDA at INR 15 crore, although margins eased versus last year as inflationary costs and higher overheads flowed through.

The quarter’s headline numbers did not carry any surprise. PAT came in at INR 3 crore versus INR 4 crore a year ago. Finance costs remained meaningful at INR 6 crore, and depreciation was INR 5 crore, reflecting the capital intensity of sterile manufacturing. What mattered more was the context management highlighted: expansion assets are expected to start contributing from Q2FY27 onwards, and captive solar generation began toward the end of Q1FY27 with benefits expected across FY27.

Amanta’s profile remains that of a niche sterile liquids company with three decades of operating history, a single WHO-GMP facility in Gujarat, seven production lines, and a portfolio of 47 products across six therapeutic segments. It sells domestically through branded distribution and exports to emerging and semi-regulated markets, with product registrations across 120 international jurisdictions. In Q1FY27, the business continued to run close to peak utilisation, signalling demand visibility but also reinforcing why the next phase is tied to commissioning new capacity.

Q1FY27 performance: growth with margin pressure, but execution stays steady

The top line in Q1FY27 reflected incremental growth on an already high base. Revenue of INR 69 crore compared with INR 77 crore in Q4FY26, indicating the quarter was lower sequentially, but the year-on-year trend remained intact. The company described the quarter as being delivered with the same capacity, which is consistent with the high utilisation levels it has reported across its LVP, SVP, and SteriPort lines.

EBITDA at INR 15 crore matched Q1FY26 in absolute terms, but the margin shifted. The investor presentation reported Q1FY27 EBITDA margin at about 21 to 22 percent, compared with 23 percent in Q1FY26. The management note pointed to inflationary cost increases and overheads as key drags. Employee costs also rose year-on-year, with Q1FY27 employee costs at INR 12 crore versus INR 10 crore in Q1FY26, reflecting a larger cost base to support scale-up and commercial execution.

Below EBITDA, finance costs stayed at INR 6 crore, unchanged year-on-year, while depreciation also remained stable at INR 5 crore. That combination left PBT at INR 5 crore, flat year-on-year, and PAT at INR 3 crore versus INR 4 crore. The quarter therefore looked like an operating stability story rather than a breakout profitability quarter.

The operating engine: sterile liquids at scale, with technology differentiation

Amanta’s investment case is anchored in sterile liquids manufacturing at scale, and specifically in its mix of Large Volume Parenterals and Small Volume Parenterals. Its Gujarat site spans 66,852 square metres and is supported by ABFS and ISBM technologies. It is ISO certified and WHO-GMP certified, and produces injections, sterile liquids, eye care products, and respiratory solutions.

The company’s technology differentiation is central to how it positions margins and competitive advantages. ABFS allows bottles to be formed, filled, and sealed in one automated step with zero human contact, with features like nitrogen purging for sensitive formulations such as paracetamol. ISBM, in contrast, is a multi-stage operation that uses preforms and produces polypropylene bottles from 100 ml upward, with air wash and WFI wash steps before filling and sealing.

SteriPort is the flagship expression of this technology push. The company highlighted being the first in India to shift from BFS to ISBM, and it described dominance in the PP IV bottle segment. SteriPort’s current capacity is 6.62 crore bottles, with 91 percent capacity utilisation, and it contributes 44 percent of revenue. It covers the 100 to 1000 ml range with in-house capabilities and uses random co-polymer polypropylene for higher tensile strength and barrier properties, and sterilisation compatibility above 121.1 degrees Celsius. The system is designed as a closed system with a two-port configuration and tamper evident closure.

The broader product portfolio remains diversified. Fluid therapy remains the largest segment at 63 percent of revenue share across categories, followed by formulations at 17 percent and diluents and injectables at 9 percent. On the SVP side, the company has inhalation solutions and ophthalmic products as meaningful growth areas, and it emphasised preservative-free unit doses and respules as portfolio expansion themes.

Operationally, utilisation rates underline a company that has been sweating assets. In FY26, utilisation stood at 91 percent for LVP, 98 percent for SVP, and 90 percent for SteriPort. The presentation summarised this as current utilisation of 96 percent overall, pointing to strong demand visibility and efficient asset use. That also clarifies why management’s near-term focus is commissioning expansion lines across LVP and SVP and adding capacity for SteriPort.

Growth levers for FY27: capacity commissioning and structural cost actions

Amanta’s stated growth levers rest on three strategic pillars: market depth, manufacturing expansion, and efficiency. The market depth theme is about wallet share expansion through complex dosages and niche molecules across anti-infectives, respiratory care, and ophthalmics. The manufacturing theme is explicit: capacity expansion aimed at scaling high-margin SteriPort and SVP capacities, with incremental capacities of 5.39 crore units and 10.78 crore units respectively, with commissioning expected in Q2FY27 and Q4FY27.

The company’s guidance framing in the presentation is ambitious for the next two years: revenue CAGR of 20 percent plus and EBITDA margin of 25 percent plus. That ambition needs to be read alongside the current utilisation levels. If the existing base is already running near peak, growth targets become heavily dependent on the timing and ramp-up of new lines, as well as the ability to fill those lines with export expansion, new products, and deeper domestic penetration.

SteriPort capacity expansion is one of the most tangible catalysts. The presentation outlined an increase from 6.6 crore bottles in FY25 to an estimated 11.6 crore bottles in FY27P. Management also indicated that the new line in the same plant can create fixed cost leverage and is expected to generate incremental revenue of INR 110 to 120 crore per year, with EBITDA margin expanding by 3 to 4 percent. If delivered, this is meaningful because SteriPort already contributes 44 percent of revenue and commands premium pricing.

SVP is positioned as a high-margin segment and export-centric. In FY26, SVP contributed 20 percent of revenue and operates at EBITDA margins of 22 to 27 percent. The capacity expansion targets an increase from 20.9 crore units in FY25 to 31.7 crore units in FY27P. The growth intent is aligned with inhalation solutions, OTC portfolio, and preservative-free unit doses.

Efficiency is the other near-term lever. A captive solar power plant of 10.8 MW is under implementation and was commissioned in Q1 FY27, with benefits expected to be reflected from FY27 onwards. The project cost is INR 34.8 crore, largely debt-funded, with annual savings expected at INR 9 crore and a payback period of 3.6 years on a pre-interest basis. The company expects these savings to support EBITDA margin improvement while also strengthening its ESG profile through lower carbon footprint.

Financial foundation: revenue consistency, capex cycle, and de-leveraging momentum

Amanta’s annual numbers show a business that has maintained revenue consistency while improving profitability and reducing leverage. Revenue from operations increased to INR 288 crore in FY26 from INR 275 crore in FY25 and INR 259 crore in FY23. EBITDA improved to INR 63 crore in FY26 from INR 61 crore in FY25 and INR 56 crore in FY23. PAT rose to INR 15 crore in FY26 from INR 11 crore in FY25, reversing the loss of FY23.

A key narrative shift has been in capital allocation and balance sheet structure. FY26 capex was INR 120 crore, sharply higher than FY25 at INR 10 crore, reflecting the current expansion cycle. This capex is visible in the balance sheet through capital work-in-progress of INR 82 crore in FY26, compared with INR 7 crore in FY25.

The company also reported a sharp rise in cash and cash equivalents to INR 81 crore in FY26 from near zero in FY25. The cash flow statement shows operating cash flow of INR 48 crore in FY26, investing cash flow of minus INR 94 crore, and financing cash flow of INR 126 crore, indicating that financing inflows funded a large part of the capex and built a cash buffer.

De-leveraging remains a stated priority and appears to be progressing. The company reported reducing total borrowings by over INR 30 crore and highlighted that the debt to equity ratio improved from 3.43 times in FY23 to 1.06 times in FY26, a reduction of over 70 percent. Debt service coverage ratio also improved to 1.24 times in FY26 from 0.37 times in FY25.

At the same time, investors should note that absolute borrowings remain substantial. In FY26, non-current borrowings were INR 162 crore and current borrowings were INR 72 crore. The improvement in debt to equity was also supported by a significant increase in net worth to INR 220 crore in FY26 from INR 96 crore in FY25, alongside expanded equity share capital and other equity.

Distribution and export strategy: margin mix is the next swing factor

The company’s distribution model spans three channels: domestic branded products through 320 plus distributors, exports to emerging and semi-regulated markets, and product partnering. The domestic footprint includes about 96 sales and marketing personnel and a pan-India distribution network.

Export expansion is a recurring lever for margin improvement. The presentation notes exports to 21 countries as of fiscal 2025, while also referencing a broader country count in fiscal year 26. Product registrations span 120 international jurisdictions, which helps create optionality across markets. Expansion targets include regulated markets such as the UK and also specific markets where GMP conformity or certifications have relevance, including Zimbabwe, Sudan, Cambodia, Philippines, and Ethiopia.

The export portfolio spans LVP pack solutions such as IV solutions and certain formulations, and SVP pack solutions such as sterile water for injection, ophthalmic products, injections, and respiratory products. Management also highlighted new product offerings in inhalation solutions and ophthalmics. If the new SVP capacity is filled with export-heavy respiratory and ophthalmic products, the margin profile could improve, given the segment’s stated 22 to 27 percent EBITDA margins.

What to watch from here

Q1FY27 looked like a transition quarter. It delivered steady revenue growth with stable EBITDA, while costs and below-the-line items kept net profit softer. The more important message is that Amanta is approaching the commissioning phase of a capex cycle that was already reflected in FY26 financial statements. If commissioning timelines hold for Q2FY27 and Q4FY27, the company should see capacity constraints ease and fixed cost leverage begin to show up.

The near-term monitoring points are straightforward. First, the ramp-up of the SteriPort expansion and its impact on revenue, especially since the company expects incremental revenue of INR 110 to 120 crore per year and a 3 to 4 percent EBITDA margin expansion from this addition. Second, the realisation of the solar project’s INR 9 crore annual savings in reported margins through FY27. Third, the mix shift between domestic and export markets, especially in SVP, where the company already reports a higher margin band.

Amanta’s quarterly theme in Q1FY27 was disciplined execution under capacity tightness, with the next phase tied to commissioning and efficiency gains. Investors are likely to judge FY27 less on Q1’s reported profitability and more on whether the company converts its near-peak utilisation and expanded capacity into sustained growth, while keeping leverage moving down.